493 results about "Xanthine" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.

The invention relates to an application of sea cucumber intestine polysaccharide in preparation of uric acid lowering drugs. The preparation method of the sea cucumber intestine polysaccharide comprises the following steps: performing enzymolysis treatment on sea cucumber intestines by using papain, performing enzyme deactivation, performing centrifugation, and taking supernate; and carrying out graded alcohol precipitation on the supernate, centrifuging, taking precipitate, deproteinizing and freeze-drying. The preparation method is simple, green and environment-friendly. The sea cucumber intestine polysaccharide prepared by the method can effectively inhibit the activity of xanthine oxidase; the sea cucumber intestine polysaccharide has no toxic effect on HK-2 cells. The compound has a uric acid reducing effect on HK-2 hyperuricemia cells.

The invention discloses camel milk polypeptide with xanthine oxidase inhibitory activity and application thereof.The camel milk polypeptide is prepared by taking fresh camel milk as a raw material, conducting low-temperature centrifugation to remove fat, conducting triple enzymolysis through papain, pepsin and trypsin to obtain enzymatic hydrolysate, enabling the enzymatic hydrolysate to pass through an ultrafiltration membrane (the molecular weight cutoff is 10 kDa) to obtain filtrate, and conducting freeze-drying to obtain the camel milk polypeptide. The compound has xanthine oxidase inhibitory activity. The invention also discloses a small molecule polypeptide with xanthine oxidase inhibitory activity. The filtered solution is screened and combined with polypeptides by adopting a xanthine oxidase affinity ultrafiltration method, the activity of the polypeptides is verified through molecular docking and in-vitro enzyme inhibition, four small-molecule polypeptides with xanthine oxidase inhibitory activity are obtained, the sequence of the small-molecule polypeptides is shown as any one of SEQ ID NO.1-4, and the small-molecule polypeptides can be used for preparing drugs with the effect of inhibiting the uric acid level.

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

The invention relates to euphausia superba peptide with uric acid reducing activity and application thereof. The euphausia superba peptide is a short peptide obtained by extraction, enzymolysis, separation and purification from degreased euphausia superba powder, and the amino acid sequence of the euphausia superba peptide is Ser-Ala-Gly-Lys-Thr. Researches show that the peptide can reduce the generation of uric acid by inhibiting the activity of xanthine oxidase and promote the excretion of uric acid. In-vitro cell experiments prove that under the concentration of 10 mu M, the inhibition rate of the peptide on xanthine oxidase reaches 23.1%; animal experiments show that the blood uric acid level of mice in a high-dose group (50mg / kg) is reduced by about 40% compared with that in a model group. The invention also develops a health-care beverage and a medicinal preparation which take the peptide as an active component, and provides a new choice for preventing and treating hyperuricemia and gout.

The present invention is a composition for caring for and / or making up keratin materials, in particular the skin, in the form of a water-in-oil emulsion comprising, in particular in a physiologically acceptable medium: a) at least one continuous oily phase comprising i) at least one volatile oil and ii) at least one nonvolatile oil; and b) at least one aqueous phase dispersed in said oily phase, wherein the amount of water is less than 20.0% by weight relative to the total weight of the composition; and c) at least one hydrophobic film-forming polymer; and d) at least one emulsifying surfactant chosen from linear polyoxyalkylenated polydimethylmethylsiloxanes with an HLB ≤ 8.0; and e) at least one hyaluronic acid; and f) at least one vitamin B3 and / or a derivative thereof; and g) at least one xanthine base and / or a plant extract containing same.

According to the preparation method disclosed by the invention, the whole fruit juice of the lonicera caerulea (which retains fruit residues) is fermented by virtue of the plant lactobacillus KLDS1.0391, KLDS1.0320 or KLDS1.0368, so that the xanthine oxidase (XO) inhibition activity is remarkably improved. After fermentation, the XO inhibition rate is increased to 48-50.87% (the content of unfermented juice is 31.21%), the total phenol content is increased by 15-24.3%, and the contents of main XO inhibitors in the lonicera caerulea: cyanidin-3-O-glucoside (IC50 = 115.28 [mu] M), cyanidin-3, 5-diglucoside (IC50 = 116.34 [mu] M), peonidin-3-glucoside (IC50 = 105.34 [mu] M), quercetin (IC50 = 88.75 [mu] M), catechin (IC50 = 110 [mu] M) and caffeoylquinic acid (IC50 = 250.35 [mu] M) are remarkably increased. Wherein the quercetin content is increased by 73.8% at most (KLDS1.0320 strain fermentation is performed for 24 hours), and the XO inhibition rate is increased from 31.21% to 50.87%. Technical support is provided for development of a natural XO inhibitor and a functional fermented beverage, so that a new thought is provided for functional fermented juice with lonicera caerulea as a key component.

The invention relates to application of plant lactobacillus FBL002 in degradation of purine nucleoside, and belongs to the technical field of microorganisms. The plant lactobacillus FBL002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on March 13, 2025, and the preservation number is GDMCC No.66015. The strain is separated from healthy infant intestinal flora, and can effectively degrade various purine nucleosides including inosine, guanosine, adenosine, guanine and adenine, so that the plant lactobacillus FBL002 is used for developing products for degrading purine nucleosides. In addition, the strain is also suitable for preparing oral hyperuricemia treatment medicines, and the contents of uric acid, xanthine oxidase and adenosine deaminase in serum can be remarkably reduced. The invention provides a safe and efficient method for managing purine metabolism abnormality related diseases by utilizing the biodegradation activity of the plant lactobacillus FBL002, and is particularly suitable for preventing and treating hyperuricemia.

The invention discloses a hexapeptide TE6 with xanthine oxidase inhibitory activity and a preparation method and application thereof, and belongs to the technical field of small molecule peptides. The amino acid sequence of the hexapeptide TE6 is TIATVE, and the hexapeptide TE6 can be prepared through a solid-phase synthesis method and an enzymolysis method. The hexapeptide TE6 is identified from a solieria cavaleriei proteolysis solution and has potential interaction with xanthine oxidase, under the concentration of 0.1 mg / mL, the xanthine oxidase inhibition rate is 44.74%, and compared with goose carnosine (the xanthine oxidase inhibition rate is 36.03%), the xanthine oxidase inhibition rate is remarkably increased (plt; 0.05), which is stronger in xanthine oxidase inhibitory activity, and can be used for preparing a preparation for inhibiting xanthine oxidase activity and relieving hyperuricemia.

The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus mucus BU360 with the function of improving uric acid, blood fat and blood glucose metabolism and application of the lactobacillus mucus BU360. The preservation number of the lactobacillus fermentum BU360 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.33032. The lactobacillus fermentum BU360 provided by the invention has the advantages that the preservation number is CGMCC No.33032; the lactobacillus mucus BU360 can efficiently degrade guanosine and inosine which are precursor substances for synthesizing uric acid and directly degrade the uric acid, thalli, cell contents and metabolites of the lactobacillus mucus BU360 can inhibit the activity of xanthine oxidase and relieve HUA, and the lactobacillus mucus BU360 can directly degrade cholesterol and inhibit the activity of alpha-glucosidase and alpha-amylase, so that the lactobacillus mucus BU360 can be used for preparing the uric acid. The polypeptide has potential capability of improving blood fat and blood glucose metabolism abnormality, and assists in treatment of HUA; besides, the strain has relatively strong acid-resistant and cholate-resistant characteristics, can smoothly reach the intestinal tract of a human body, has relatively good safety on sensitivity of various antibiotics, and lays a foundation for development of related probiotic products. The lactobacillus mucus BU360 has a wide application prospect in the aspect of preparing products for relieving HUA, improving blood fat and blood glucose metabolism and the like.

The invention discloses an EGCG-Cu complex, an EGCG-Cu-Cs nanoparticle, a preparation method of the EGCG-Cu complex, and an application of the EGCG-Cu-Cs nanoparticle. The preparation method comprises the following steps: mixing an aqueous solution of EGCG and an aqueous solution containing copper ions, adjusting the pH value, stirring for reaction, dialyzing or centrifuging, and freeze-drying to obtain the EGCG-Cu complex; the EGCG-Cu complex is dissolved in water, a chitosan solution is added, stirring reaction, centrifugal washing and freeze drying are carried out, and the EGCG-Cu-Cs nanoparticles are obtained. The EGCG-Cu complex and the EGCG-Cu-Cs nanoparticles prepared by the invention are uniform in size and good in dispersity, and have excellent xanthine oxidase inhibition effect and free radical scavenging effect.

The invention belongs to the technical field of sensors, and relates to an array sensor based on cerium-based metal organic framework nano-enzyme and detection application of perfluoroalkyl compounds. The array sensor is a Ce-MOF triple enzyme activity array sensor and is provided with a plurality of mutually independent sensing channels; the sensing channel contains a Ce-MOF nano enzyme and a chromogenic substrate; the chromogenic substrates comprise a first chromogenic substrate, a second chromogenic substrate and a third chromogenic substrate, the first chromogenic substrate comprises 3, 3 ', 5, 5'-tetramethyl benzidine, the second chromogenic substrate comprises 2, 4-diaminophenol and 4-aminoantipyrine, and the third chromogenic substrate comprises xanthine, purine oxidase and nitrogen blue tetrazole. The MOF nano-enzyme array sensor constructed by the invention has relatively high sensitivity and selectivity in identification and distinguishing of PFASs compounds, not only can accurately distinguish single PFASs compounds, but also can perform quantitative detection, and has good response to PFASs with different concentrations.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention discloses a uric acid reducing composition and a preparation method and application of plant extracts of the uric acid reducing composition, and belongs to the technical field of traditional Chinese medicine formulas and preparation. The uric acid reducing composition is prepared from the following raw materials in parts by mass: 3 to 27 parts of corn stigma, 3 to 27 parts of pericarpium citri reticulatae and 3 to 27 parts of white kidney beans. The preparation method of the plant extract comprises the following steps: pretreating the raw materials, extracting effective components, compounding according to different proportions, evaluating the in-vitro xanthine oxidase inhibition effect by using the plant extract, determining the formula compatibility of the raw materials according to quantitative pharmacology, and further determining the formula compatibility of the uric acid reducing composition. The corn stigma is treated by adopting a steam wall breaking technology, so that the extraction rate of effective components of the corn stigma is remarkably improved, and the uric acid reducing effect of the product is enhanced; the uric acid reducing food prepared on the basis of the uric acid reducing composition is safe, free of side effects and suitable for being eaten by people with high uric acid for a long time.

The invention provides peony polypeptide for reducing uric acid as well as a preparation method and application thereof, and belongs to the technical field of biology. The preparation method comprises the following steps: soaking and cleaning peony seed meal with ethanol, centrifuging at 3000-500r for 30-50min, taking a first precipitate, drying the first precipitate, adding water, adjusting the pH value to 9-10, carrying out alkali extraction at 45-55 DEG C for 70-80min, taking supernate, adjusting the pH value to an isoelectric point, and taking a second precipitate; the second precipitate is subjected to enzymolysis for 2-8 h under the conditions that the temperature is 20-80 DEG C, the pH is 5-9, and the protease addition amount is 1500-9000 U / g, and the peony polypeptide capable of reducing uric acid is obtained. The compound has inhibitory activity on xanthine oxidase, and the active components of the compound have stability and functionality by adopting ultrafiltration grading and simulated digestion model exploration.

The invention discloses a targeted screening method and application of a xanthine oxidase inhibitor in radix puerariae, and belongs to the technical field of medicinal chemistry. A surface chemical exchange method is carried out on xanthine oxidase through a ligand fishing technology, ligands of active groups of xanthine oxidase are modified to the surfaces of magnetic metal nanoparticles, the magnetic metal nanoparticles and a to-be-separated solution are incubated together, and then specific components with the xanthine oxidase inhibiting effect are successfully screened out through a UPLC-Q-TOF-MS / MS technology. The combination of the active component and the XOD active site is verified through molecular docking simulation to confirm that the active component is an effective inhibitor. The invention provides a reliable basis for further clinical research and development of drugs for treating hyperuricemia, and has a wide application prospect.

The invention discloses a uric acid reducing polypeptide, the polypeptide is derived from a peptide fragment, the'bindingerge 'value of the peptide fragment in molecular docking with xanthine oxidase is less than-1.5 kcal / mol, and the peptide fragment, in molecular docking with the xanthine oxidase, of the polypeptide is derived from a Peptide Ranker biological activity score gt; and 0.7 of a polypeptide. The uric acid reducing polypeptide is obtained by screening natto powder subjected to pepsin enzymolysis, natto powder enzymatic hydrolysate obtained through enzymolysis has the activity of inhibiting xanthine oxidase, the screened uric acid reducing polypeptide can be developed into a uric acid reducing medicine, and active ingredients are added into functional food and health food, so that the uric acid reducing polypeptide has a good application prospect. Good market prospects are realized in medicine and food industries.

There is provided a method for diagnosing a subject with early onset muscle atrophy, said method comprising: obtaining a biosample from the subject; and assaying the biosample for one or more biomarkers, said one more biomarkers are taurine, proline, citrulline, trigonelline, thymidine, ornithine, glutamate, L-pyroglutamic acid, creatinine, adenine, nicotinamide, 2-methylhippuric acid, maltol, L-arginine, hypotaurine, L-glutamine, homogentisic acid, methylhistidine, oxoglutaric acid, xanthine, L-carnitine, succinate, or a combination thereof; and identifying the subject with early onset muscle atrophy on the basis of a deviation in the one or more of said one more biomarkers.

Disclosed are an aqueous American ginseng extract, a method for preparing, and use thereof in reducing uric acid. The method comprises the following steps: grinding American ginseng, mixing with petroleum ether, and subjecting the mixture to ultrasonic extraction and filtration at reduced pressure; drying the defatted American ginseng powder and mixing with deionized water, and subjecting the mixture to another ultrasonic extraction and filtration at reduced pressure to give an aqueous American ginseng extract solution; and concentrating and lyophilizing the aqueous American ginseng extract solution to give the aqueous American ginseng extract. The resultant aqueous American ginseng extract can effectively reduce the activity of xanthine oxidase and adenosine deaminase, lower the blood uric acid level, and provide certain protective effects on the kidneys, thus possessing good development prospects.

It is unequivocal that to facilitate targeted antimicrobial prescribing practices and to help reduce the increasing global burden of antibiotic resistance, there is an urgent need for the development of novel and truly rapid (less than or equal to 1 hour) AST platforms. A 785 nm SERS based methodology is described that results in accurate MIC determinations for all tested strain / antibiotic pairs following a 30 minute drug incubation period. The time for an SERS AST result is -1 hour. The SERS-AST method works for both Gram positive and Gram negative species and for all primary mechanisms of antibiotic activity. Agreement with 24 hour growth determined MICs is obtained for both bactericidal and bacteriostatic antibiotics although different patterns of dose dependent SERS intensities characterize these two types of antibiotics. Bacterial SERS spectra due to secreted purine nucleotide degradation products (principally adenine, guanine, xanthine and hypoxanthine).

The invention relates to an electrochemical sensor for detecting xanthine, the electrochemical sensor is a three-electrode system, a working electrode of the electrochemical sensor is prepared by preparing a modification solution from Cu-BTC-HHTP-HCG and dispensing the modification solution on the surface of a glassy carbon electrode, and the Cu-BTC-HHTP-HCG is synthesized from copper nitrate trihydrate, 1, 3, 5-benzene tricarboxylic acid, 2, 3, 6, 7, 10, 11-hexahydroxy triphenylene hydrate and high-conductivity graphene. According to the electrochemical sensor for xanthine detection, Cu-BTC-HHTP has high electrocatalytic activity, specific surface area and porosity, the enrichment efficiency and electron transfer capability of xanthine can be effectively improved, meanwhile, the conductivity and stability of the electrochemical sensor can be further enhanced through compounding of high-conductivity graphene, and the electrochemical sensor can be applied to xanthine detection. Therefore, the electrochemical sensor is endowed with excellent electrochemical response performance. The electrochemical sensor is high in sensitivity, low in detection limit, good in stability and interference resistance and suitable for detecting xanthine in actual fish and shrimp products.

The invention relates to the field of growth-promoting bacteria, in particular to screening and application of saline-alkali soil crop growth-promoting bacteria, and discloses a screening method and application of the saline-alkali soil crop growth-promoting bacteria. Through gradient domestication, multi-index function verification and molecular identification, a strain which is salt-tolerant, can efficiently solubilize phosphorus (more than 150 mu g / mL), can secrete IAA (more than 30 mg / L) and has nitrogenase activity more than 20 IU / L is screened from rhizosphere soil with salt concentration of 0.8%-1.2% and pH of 7.8-8.5. Screened strains are compounded with a carrier (the ratio of decomposed sheep manure to attapulgite to humic acid to xanthine is (70-75): (20-25): (8-10): (0.3-1)), the complex microbial inoculant is prepared through secondary fermentation, and a final field test shows that the yield of corn can be increased by 18%-32%, the pH of soil is reduced by 0.5-1.0, the salinity is reduced by 0.2%-0.5%, the saline-alkaline environment is remarkably improved, and the complex microbial inoculant has a wide application prospect.

The invention discloses a preparation method and application of hydrolyzed casein peptide capable of reducing uric acid and facilitating gout attack prevention and gout symptom improvement, belongs to the technical field of biology, and has a wide application prospect. The casein hydrolysate peptide prepared by the method disclosed by the invention can effectively reduce uric acid, and is beneficial to preventing gout attack and improving gout symptoms by the following ways: 1, inhibiting the activity of xanthine oxidase (UA enzyme), and reducing the generation of uric acid; 2, metal ions such as Ca < 2 + > and Na < + > are complexed to prevent generation of urate crystals, so that gout attack can be prevented; 3, the microenvironment of an articular cavity is improved, urate crystals are dissolved, and the gout symptom can be improved; and 4, liver and kidney inflammation caused by high uric acid is relieved.

The invention belongs to the field of traditional Chinese medicine prescription extraction process optimization, and particularly relates to a method for optimizing a classic famous prescription Xiaoxiaoxiao decoction extraction process based on orthogonal combination benchmark correlation degree and an AHP-entropy weight method. According to the invention, quality evaluation is carried out on the extraction process by taking the quality of a reference sample as a reference standard, orthogonal design is selected, and a relatively comprehensive quality control system taking the contents of vanillic acid, hypoxanthine, jateorhizine, coptisine, palmatine and berberine as well as fingerprint similarity and dry extract rate as comprehensive evaluation indexes is established; the limitation of the traditional single index on the quality control of the extraction process is avoided. A combined weighting method combining AHP and an entropy weight method is adopted, the defects caused by single weighting are overcome, and a reference is provided for modern preparation development of the classic famous prescription Xiaoxiaoxi decoction.